Enimmune Valuation
Is 6564 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6564 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6564's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6564's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6564?
Key metric: As 6564 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 6564's PS Ratio? | |
|---|---|
| PS Ratio | 40.9x |
| Sales | NT$50.82m |
| Market Cap | NT$2.08b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 34.3x |
| Enterprise Value/EBITDA | -7.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6564's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.9x | ||
6704 Gwo Xi Stem Cell Applied Technology | 17.9x | n/a | NT$2.7b |
6645 Kim Forest Enterprise | 3.2x | n/a | NT$1.5b |
3164 GenMont Biotech Incorporation | 4.7x | n/a | NT$1.7b |
4194 Holy Stone Healthcare | 9.7x | n/a | NT$2.2b |
6564 Enimmune | 40.9x | n/a | NT$2.1b |
Price-To-Sales vs Peers: 6564 is expensive based on its Price-To-Sales Ratio (40.9x) compared to the peer average (8.9x).
Price to Sales Ratio vs Industry
How does 6564's PS Ratio compare vs other companies in the TW Biotechs Industry?
Price-To-Sales vs Industry: 6564 is expensive based on its Price-To-Sales Ratio (40.9x) compared to the TW Biotechs industry average (20.9x).
Price to Sales Ratio vs Fair Ratio
What is 6564's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 40.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6564's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
RBC Bioscience
NT$254.3m
Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.
6848
NT$19.60
7D
-0.5%
1Y
29.8%
YungShin Global Holding
NT$15.4b
Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.
3705
NT$57.90
7D
8.2%
1Y
27.1%
Cenra
NT$6.0b
Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.
1701
NT$21.15
7D
0%
1Y
-8.8%